Study S002662

GOaL Directed-STrategic Approach With New Disease-modifying theraApies to Reduce Kidney and Cardiovascular Risk in Patients With Diabetic Kidney Disease

Name: LivingGLP1 adjudicated trial data and network meta-analysis results
Creator: Ahmad Sofi-Mahmudi
License: https://creativecommons.org/licenses/by/4.0/

ClinicalTrials.gov record

Registration

Registration: NCT07434791
Acronym: GOLD-STANDARD
Study type: INTERVENTIONAL
Allocation: RANDOMIZED
Masking: SINGLE
Status: RECRUITING
Enrollment: 100
Start: 2026-08-26
Primary completion: 2028-09
Lead sponsor: Sunnybrook Health Sciences Centre
Conditions: Diabetic Kidney Disease (DKD); Type 2 Diabetes Mellitus (T2DM); Chronic Kidney Disease
Interventions: OTHER:Early goal-directed Cardio-Kidney-Metabolic (CKM) care; OTHER:Standard care (Comparison arm)
Results posted: FALSE
Individual participant data sharing: YES

Registered primary outcomes

Feasibility of the pivotal Randomized Controlled Trial (RCT) [From consent through completion of screening procedures to randomization (maximum 60 days).]
Prescription and Adherence to Guideline-Directed Medical Therapy (GDMT) [12 months after randomization (±45-day window).]

Linked records (8)

Automatic links, confirmed or rejected during screening. A record citing this registration may be a secondary analysis, a commentary or a review that mentions the trial.

Record	Title	Year	Design	Identifiers	Link basis
R0006013	Efficacy and safety of SGLT2 inhibitors with and without glucagon-like peptide 1 receptor agonists: a SMART-C collaborative meta-analysis of randomised controlled trials. Apperloo EM, The lancet. Diabetes & endocrinology	2024	Systematic review	PMID 38991584 DOI	registry reference BACKGROUND:38991584
R0007062	Cardiovascular, Kidney, and Safety Outcomes With GLP-1 Receptor Agonists Alone and in Combination With SGLT2 Inhibitors in Type 2 Diabetes: A Systematic Review and Meta-Analysis. Neuen BL, Circulation	2024	Systematic review	PMID 39210781 DOI	registry reference BACKGROUND:39210781
R0023703	Virtual Pharmacy: An Integrated Collaborative Redesign Targeting Medication-Related Problems in Patients with Chronic Kidney Disease. Ong SW, American journal of nephrology	2024	Other	PMID 37939689 DOI	registry reference BACKGROUND:37939689
R0004759	Biology and Clinical Use of Glucagon-Like Peptide-1 Receptor Agonists in Vascular Protection. Yau K, The Canadian journal of cardiology	2023	Narrative review	PMID 37429523 DOI	registry reference BACKGROUND:37429523
R0008898	Prescribing SGLT2 Inhibitors in Patients With CKD: Expanding Indications and Practical Considerations. Yau K, Kidney international reports	2022	Other trial	PMID 35812300 DOI	registry reference BACKGROUND:35812300
R0008800	Cardiorenal Protection in Diabetic Kidney Disease. Lee JF, Endocrinology and metabolism (Seoul, Korea)	2021	Narrative review	PMID 33873265 DOI	registry reference BACKGROUND:33873265
R0010376	Prevalence of Chronic Kidney Disease in Type 2 Diabetes: The Canadian REgistry of Chronic Kidney Disease in Diabetes Outcomes (CREDO) Study. Chu L, Clinical therapeutics	2021	Nonrandomized study	PMID 34426012 DOI	registry reference BACKGROUND:34426012
R0010389	Making a case for the combined use of SGLT2 inhibitors and GLP1 receptor agonists for cardiorenal protection. Sridhar VS, Jornal brasileiro de nefrologia	2020	Narrative review	PMID 32926067 DOI	registry reference BACKGROUND:32926067